William G. Blum

William G. Blum

Hematology Oncology
1365 Clifton Road Northeast
BldgC
Atlanta, GA 30322

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 118 publications

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2026

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

Journal: Blood
Published: May 04, 2026

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Journal: American journal of hematology
Published: April 02, 2026

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Journal: Leukemia
Published: March 31, 2026

Prognostic and Therapeutic Implications of BRAF Mutations in Acute Myeloid Leukemia.

Prognostic and Therapeutic Implications of BRAF Mutations in Acute Myeloid Leukemia.

Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.

Journal: Blood advances
Published: November 19, 2025

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Journal: Blood advances
Published: November 19, 2025

Epigenetic markers expand genetic risk estimation in acute myeloid leukemia.

Epigenetic markers expand genetic risk estimation in acute myeloid leukemia.

Journal: Blood
Published: October 02, 2025

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.

Journal: Haematologica
Published: July 24, 2025

Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia.

Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia.

Journal: JAMA network open
Published: June 23, 2025

Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.

Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.

Journal: Leukemia
Published: June 23, 2025
Showing 1-12 of 118

Last Updated: 09/26/2026